Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2008;57:684-694; doi:10.1136/gut.2006.117382
Copyright © 2008 BMJ Publishing Group Ltd & British Society of Gastroenterology.

Recent advances in clinical practice

Gut, inflammation and osteoporosis: basic and clinical concepts

H Tilg1, A R Moschen1, A Kaser1, A Pines2, I Dotan3

1 Christian Doppler Research Laboratory for Gut Inflammation and Department of Medicine, Division of Gastroenterology and Hepatology, Medical University Innsbruck, Austria
2 Department of Medicine "T", Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
3 IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel

Correspondence to:
Dr Herbert Tilg, Christian Doppler Research Laboratory for Gut Inflammation and Division of Gastroenterology and Hepatology, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria; herbert.tilg{at}i-med.ac.at

ABSTRACT

Chronic inflammatory disorders such as inflammatory bowel diseases (IBD) affect bone metabolism and are frequently associated with the presence of osteoporosis. Bone loss is regulated by various mediators of the immune system such as the pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-{alpha}), interleukin-1beta (IL-1β), IL-6, or interferon-gamma. TNF-{alpha}, a master cytokine in human IBD, causes bone erosions in experimental models and these effects are exerted by osteoclasts. Other TNF-related cytokines such as receptor activator of nuclear factor kappa B (RANK), its ligand, RANKL, and osteoprotegerin are important mediators in inflammatory processes in the gut and are critically involved in the pathophysiology of bone loss. The awareness and early diagnosis of osteoporosis in states of chronic inflammation, together with applied therapies such as bisphosphonates, may be beneficial in inflammation-associated osteoporosis. Although several mechanisms may contribute to osteoporosis in patients with IBD and coeliac disease, inflammation as an important factor has so far been neglected. As key inflammatory mediators in IBD such as TNF-{alpha} are involved in the disease process both in gut and bone, we hypothesise that neutralisation of TNF-{alpha} could prove an efficient strategy in the treatment of inflammation-related osteoporosis in the future.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs